An interferon-free combination of faldaprevir, BI 207127, and ribavirin produced high and similar sustained response rates for treatment-naive genotype 1b hepatitis C patients with either absent-to-moderate liver fibrosis or advanced fibrosis/cirrhosis, according to a presentation at the Digestive Disease Week conference (DDW 2013) this week in Orlando.
HCV viral breakthrough is a continued possibility during the pegylated interferon/ribavirin continuation phase after triple therapy with telaprevir (Incivek or Incivek or Incivo), especially for difficult-to-treat patients, researchers reported this week at the Digestive Disease Week conference (DDW 2013) in Orlando.
- Category: HCV Testing & Diagnosis
- Published on Wednesday, 15 May 2013 00:00
May 19 is the second annual Viral Hepatitis Testing Day, an opportunity to raise awareness among healthcare providers and the public about screening for chronic hepatitis B and C. According to the Centers for Disease Control and Prevention (CDC), an estimated 75% of people with hepatitis C virus (HCV) are not aware they are infected.
Treating herpes simplex virus type 2 (HSV-2) with valacyclovir (Valtrex) was associated with a substantial reduction in plasma hepatitis C virus levels in dually infected individuals, according to a small study presented at the Digestive Disease Week conference (DDW 2013)this week in Orlando.
On May 13, Janssen announced that its application for approval of the next-generation hepatitis C virus NS3/4A protease inhibitor simeprevir (formerly TMC435) has received priority review status from the U.S. Food and Drug Administration (FDA), giving it an estimated timeline of 6 months.
- Category: HCV Disease Progression
- Published on Wednesday, 22 May 2013 00:00
Probiotics that change the population of organisms in the gut can help improve neurocognitive function and prevent hepatic encephalopathy in people with liver cirrhosis, according to a presentation last month at the EASL International Liver Congress (EASL 2013) in Amsterdam.
For people with chronic hepatitis C who cannot wait for all-oral regimens, interferon-based therapy is still a reality. Researchers at the recent EASL International Liver Congress (EASL 2013) presented promising data showing that several experimental direct-acting antiviral agents (DAAs) can significantly improve response rates without reducing tolerability.
Adding the HCV protease inhibitor simeprevir (formerly TMC435) to pegylated interferon and ribavirin cured 79% of prior relapsers, and most were eligible to complete treatment after 3 months, according to findings from the PROMISE study presented at the Digestive Disease Week meeting (DDW 2013) this week in Orlando.
About half of patients taking boceprevir (Victrelis) or telaprevir (Incivek or Incivo) developed anemia and approximately one-third experienced skin rash, but sustained response rates were high in an analysis of a population representative of people with chronic hepatitis C in North America, researchers reported at the EASL International Liver Congress (EASL 2013) last month in Amsterdam.
- HCV Treatment
- HCV Prevention
- HCV Testing & Diagnosis
- HCV Disease Progression
- HCV-Related Conditions
- Side Effects - HCV
- HCV Basic Science
- HCV Epidemiology & Mortality
- HCV Populations
- HCV Policy & Advocacy
- HCV Resources